Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial

Blood

Volumn 120, Issue 16, 2012, Pages 3280-3287

  Tan, King L ^a   Scott, David W ^a   Hong, Fangxin ^b   Kahl, Brad S ^c   Fisher, Richard I ^d   Bartlett, Nancy L ^e   Advani, Ranjana H ^f   Buckstein, Rena ^g   Rimsza, Lisa M ^h   Connors, Joseph M ^a   Steidl, Christian ^a   Gordon, Leo I ⁱ   Horning, Sandra J ^j   Gascoyne, Randy D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^h UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLEOMYCIN; CD163 ANTIGEN; CD68 ANTIGEN; CHLORDANE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; MECHLOROETHAMINE; PREDNISONE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84868116570     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-421057     Document Type: Article

References (36)

1. Moccia AM, Donaldson J, Chhanabhai M, et al. The International Prognostic Factor Project Score (IPS) in advanced stage Hodgkin lymphoma has limited utility in patients treated in the modern era. J Clin Oncol. 2012;30(27):3383-3388.
2. Guisado-Vasco P, Arranz-Saez R, Canales M, et al. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leuk Lymphoma. 2012;53(5):812-819.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
4. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812-1826.
5. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica. 2011;96(2):186-189.
6. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
7. Casulo C, Arcila M, Teruya-Feldstein J, Maragulia J, Moskowitz CH. Tumor-associated macrophages are predictive of survival in relapsed and refractory Hodgkin lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):2630.
8. Touati M, Delage-Corre M, Monteil J, et al. CD68+ tumor-associated macrophages predict unfavorable treatment outcomes in classic Hodgkin's lymphoma in correlation with early FDGPET assessment results [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1558.
9. Farinha P, Rodrigues S, Fernandes T, et al. Lymphoma associated macrophages predict survival in uniformly treated patients with classical Hodgkin lymphoma [abstract]. Mod Pathol. 2011;24(1 Suppl):1257.
10. Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68 and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome [prepublished online ahead of print October 8, 2012]. J Clin Oncol.
11. Deau B, Bachy E, Ribrag V, et al. Macrophages and mast cells infiltration are biomarkers of primary refractory Hodgkin's lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):3881.
12. Sánchez-Espiridión B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. Haematologica. 2012;97(7):1080-1084.
13. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology. 2010;77(6):301-308.
14. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma. 2011;52(10):1913-1919.
15. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol. 2012;88(4):292-305.
16. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011;96(2):269-276.
17. Zaki MA, Wada N, Ikeda J, et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch. 2011;459(4):361-366.
18. Agostinelli C, Gallamini A, Rigacci L, et al. The prognostic value of biologic markers in classical Hodgkin lymphoma (CHL) patients [abstract]. Ann Oncol. 2011;22(Suppl 4):153-154.
19. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 2012;7:12.
20. Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2012;23(3):736-742.
21. Swerdlow SH, Harris NL, Jaffe ES, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
22. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252-7259. (Pubitemid 39487712)
23. Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne RW. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis. 2004;63(7):774-784. (Pubitemid 38850447)
24. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122(5):794-801. (Pubitemid 39434761)
25. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011;9:216.
26. Ambarus CA, Krausz S, van Eijk M, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2012;375(2):196-206.
27. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010;47(8):1650-1660.
28. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11(11):750-761.
29. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol. 2011;41(9):2522-2525.
30. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-737.
31. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167(2):195-205.
32. Fukuda K, Kobayashi A, Watabe K. The role of tumor-associated macrophage in tumor progression. Front Biosci (Schol Ed). 2012;4(Suppl 4): 787):787-798.
33. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-969.
34. Stables MJ, Shah S, Camon EB, et al. Transcriptomic analyses of murine resolution-phase macrophages. Blood. 2011;118(26):e192-e208.
35. Hohaus S, Santangelo R, Giachelia M, et al. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011;17(9):2885-2892.
36. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009;113(12):2765-3775.